Benzodiazepines and Z drugs linked to risk of Alzheimer's disease

Use of benzodiazepines and related drugs is associated with a slightly increased risk of developing Alzheimer's disease, a Finnish study suggests.

A Finnish study has concluded that benzodiazepines and Z drugs are associated with a 6% increase in the odds of developing Alzheimer's disease. I

The case-control study, published in Acta Psychiatrica Scandinavica, found that the use of benzodiazepines and Z drugs such as zolpidem and zopiclone was associated with a 6% increase in the odds of developing Alzheimer's disease.

Despite the modest level of the association, the authors conclude that the use of benzodiazepines and Z drugs should be avoided where possible and the drugs should be prescribed only when the benefit outweighs the risk of adverse effects.

Further information

Acta Psychiatr Scand article

The study included data on all 70,719 community-dwelling Finnish people diagnosed with Alzheimer's disease between 2005 and 2011 and compared them with 282,862 matched controls without Alzheimer's disease, in terms of benzodiazepine and related drug use since 1995.

The study found a dose-response relationship between benzodiazepine and Z drug use and Alzheimer's risk for both duration and cumulative use. This association disappeared when use of other psychotropic drugs such as antidepressants and antipsychotics was taken into account, suggesting it could be partially explained by these medicines or their concomitant use.

No major differences in the association with Alzheimer's disease were found between the different subcategories of benzodiazepines, such as long or short-acting agents.

Risks of benzodiazepines and Z drugs

The findings of the study are important, say the authors, because benzodiazepines are commonly prescribed to older people. Although Z drugs are non-benzodiazepine hypnotics they act at the benzodiazepine receptor and have similar effects.

Both classes of drugs can have negative short-term effects, particularly in older people. These include ataxia and confusion, leading to an increased risk of falls, fractures and injuries.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...